Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.52 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.45 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | CETP | P11597 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24962970 | 0.93 | GPR119 (0.57) | GPR119TIPARPACACBCHRM2CHRM1 | |
| SCHEMBL31027274 | 0.86 | CHRM2 (0.46) | GPR119TIPARPACACBCHRM2CHRM1 | |
| SCHEMBL30877449 | 0.85 | GPR119 (0.53) | GPR119ACACBCHRM2CHRM1CHRM3 | |
| SCHEMBL24467795 | 0.84 | GPR119 (0.55) | GPR119ACACBCHRM2CHRM1CHRM3 | |
| SCHEMBL27173051 | 0.82 | TIPARP (0.47) | TIPARPACACBCHRM2CHRM1HDAC1 | |
| SCHEMBL25310609 | 0.81 | GPR119 (0.49) | GPR119EIF2AK4HSD11B1 | |
| SCHEMBL25309533 | 0.80 | GPR119 (0.59) | GPR119CHRM2CHRM1CHRM3RET | |
| SCHEMBL31410387 | 0.80 | GPR119 (0.45) | GPR119TIPARP | |
| SCHEMBL31410454 | 0.80 | GPR119 (0.45) | GPR119TIPARP | |
| SCHEMBL31381887 | 0.80 | GPR119 (0.45) | GPR119TIPARP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240336596-A1 | PARP7 INHIBITOR AND USE THEREOF | NOVOSTAR PHARMACEUTICALS, LTD. (CN) | 2024-10-10 | — | — | US | disclosed |
| CN-115785074-B | PARP7 inhibitors and uses thereof | 诺沃斯达药业(上海)有限公司 | 2024-05-07 | — | — | CN | disclosed |
| EP-4338737-A1 | PARP7 INHIBITOR AND USE THEREOF | Novostar Pharmaceuticals, Ltd. (CN) | 2024-03-20 | — | — | EP | disclosed |
| WO-2023185073-A1 | PARP7 INHIBITOR AND USE THEREOF | 诺沃斯达药业(上海)有限公司 | 2023-10-05 | — | — | WO | disclosed |
| WO-2023185073-A1 | PARP7 INHIBITOR AND USE THEREOF | 诺沃斯达药业(上海)有限公司 | 2023-10-05 | — | — | WO | disclosed |
| WO-2023139536-A1 | (4-PIPERAZIN-1YL)-4-ALKYL-PHTHALAZIN-1(2H)-ONE COMPOUNDS AS PARP7 INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2023-07-27 | — | — | WO | disclosed |
| CN-115785074-A | PARP7 inhibitors and uses thereof | 诺沃斯达药业(上海)有限公司 | 2023-03-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336596-A1 | PARP7 INHIBITOR AND USE THEREOF | PARP1, PARP3, PARP11 | GPR119 2682/4885TIPARP 54/4885ACACB 2059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.